2013 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
07/30/13REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS
WASHINGTON & SAN FRANCISCO – July 30, 2013 – REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease using NAV vectors.Under the terms of the Agreement, REGENX granted Audentes an exclusive worldwide license, with rights to sublicense, to REGENX’s NAV rAAV8 and rAAV9 vectors for treatment of XLMTM and Pompe... 
Printer Friendly Version
07/18/13AUDENTES THERAPEUTICS RAISES $30 MILLION IN SERIES A FINANCING
Funding creates premier global biotechnology company dedicated to the development of treatments for rare muscle diseases using gene therapy technologySAN FRANCISCO, CA. – July 18, 2013 – Audentes Therapeutics Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing. The financing was led by OrbiMed Advisors with the participation of 5AM Ventures and Versant V... 
Printer Friendly Version